Join the Oncology Voice Network. Join for Free
The Future MSL
medical science liaison MSL role evolution future of MSL analytics in MSL MSL diversity

The Future MSL


Share This Article


Summary

In this episode, Eddie Power joins to discuss the future landscape of the Medical Science Liaison (MSL) role. The conversation delves into emerging trends, including the integration of analytics to enhance MSL functions and the evolving responsibilities that may lead to new titles. Eddie explores how data delivery and strategy will shape MSL activities, alongside expanding stakeholder engagement. The episode also provides insights on preparing current MSLs for upcoming changes and offers advice to MSL leaders on fostering diversity, equity, and inclusion within their teams. The discussion wraps up with expressions of gratitude and appreciation for the listeners.

Learn more about…

πŸ‘‰ What factors will affect the MSL job and its trajectory into the future
πŸ‘‰ What credentials will be necessary for the future MSL and what might change
πŸ‘‰ What is on the horizon that makes the MSL role better (or worse) in the future
πŸ‘‰ Is the future of the MSL role in jeopardy at all due to AI and artificial intelligence
πŸ‘‰ Will new titles and responsibilities emerge for the MSL of the future
πŸ‘‰ Will the MSL of the future be more involved with the patient

Click for Source
medical science liaison, MSL role evolution, future of MSL, analytics in MSL, MSL diversity

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
Social Media Listening Evolved
Partner Avatar MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson

Social Media Listening Evolved

Podcast
Over-Negotiation-How to Botch a Job Offer
Partner Avatar MSL Talk: Tom Caravela

Over-Negotiation-How to Botch a Job Offer

Article
Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
OVN Avatar Avi Cherla, MSc; Huseyin Naci, MHS, PhD; Aaron S. Kesselheim, MD, JD, MPH; Bishal Gyawali, MD, PhD; Elias Mossialos, MD, PhD

Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval

Podcast
Hiring Managers Beware: Reverse Rejection Explained!
Partner Avatar Michael Pietrack

Hiring Managers Beware: Reverse Rejection Explained!

Article
The Talent Inflection Point in Pharma and Biotech: A Challenge to Companies β€” and a Call to Candidates
OVN Avatar Jamie Riley

The Talent Inflection Point in Pharma and Biotech: A Challenge to Companies β€” and a Call to Candidates

Article
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
OVN Avatar Michael Z. Liao, Dan Lu, Matts KΓ₯gedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li

Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?

Explore OVN